RS
TCRX icon

R Squared’s TScan Therapeutics TCRX Stock Holding History

R Squared’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,033
Closed -$16K – 660
2025
Q4 		$16K Sell
16,033
-2,794
-15% -$4.04K 0.01% 500
2025
Q3 		$34.3K Buy
18,827
+7,646
+68% +$13.5K 0.01% 514
2025
Q2 		$16.2K Buy
+11,181
New +$16.2K 0.01% 448

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

R Squared's TCRX Position: Q1 2026 in Review

R Squared sold out of TScan Therapeutics (TCRX) in Q1 2026, closing a stake of 16,033 shares — an estimated $16K sold.

R Squared first reported a position in TCRX in Q2 2025 and held it in 3 quarters. The position peaked at $34.3K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • R Squared reported no remaining TScan Therapeutics position as of Q1 2026 after selling out during the quarter.
  • R Squared sold 16,033 TScan Therapeutics shares in Q1 2026, an estimated $16K.
  • R Squared first reported a position in TScan Therapeutics in Q2 2025 and held it in 3 quarters.
  • R Squared's TScan Therapeutics position peaked at $34.3K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.